

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL

No. 1217 Session of
2013

INTRODUCED BY STERN, MILLARD, PICKETT, SCHLOSSBERG, R. BROWN,
HEFFLEY, GRELL, V. BROWN, D. COSTA, BAKER, MARSHALL,
HICKERNELL, MAJOR, MOUL, GODSHALL, OBERLANDER, CLYMER,
SWANGER, MILLER, KORTZ, MARSICO, GINGRICH, KAUFFMAN,
CALTAGIRONE, ROCK, WATSON AND QUINN, APRIL 17, 2013

REFERRED TO COMMITTEE ON JUDICIARY, APRIL 17, 2013

AN ACT

1 Amending the act of April 14, 1972 (P.L.233, No.64), entitled
2 "An act relating to the manufacture, sale and possession of
3 controlled substances, other drugs, devices and cosmetics;
4 conferring powers on the courts and the secretary and
5 Department of Health, and a newly created Pennsylvania Drug,
6 Device and Cosmetic Board; establishing schedules of
7 controlled substances; providing penalties; requiring
8 registration of persons engaged in the drug trade and for the
9 revocation or suspension of certain licenses and
10 registrations; and repealing an act," further providing for
11 schedules of controlled substances.

12 The General Assembly of the Commonwealth of Pennsylvania
13 hereby enacts as follows:

14 Section 1. Section 4(1)(vii) of the act of April 14, 1972
15 (P.L.233, No.64), known as The Controlled Substance, Drug,
16 Device and Cosmetic Act, amended June 20, 2011 (P.L.86, No.7),
17 is amended and the paragraph is amended by adding a subparagraph
18 to read:

19 Section 4. Schedules of Controlled Substances.--The
20 following schedules include the controlled substances listed or
21 to be listed by whatever official name, common or usual name,

1 chemical name, or trade name designated.

2 (1) Schedule I--In determining that a substance comes within
3 this schedule, the secretary shall find: a high potential for
4 abuse, no currently accepted medical use in the United States,
5 and a lack of accepted safety for use under medical supervision.
6 The following controlled substances are included in this
7 schedule:

8 * * *

9 (iii.1) Any compound, except bupropion or compounds listed
10 under a different schedule, or compounds used within legitimate
11 and approved medical research, structurally derived from 2-
12 aminopropan-1-one by substitution at the 1-position with phenyl,
13 naphthyl or thiophenen ring systems, whether or not the compound
14 is further modified in any of the following ways:

15 1. By substitution in the ring system to any extent with
16 alkyl, alkylendioxy, alkoxy, haloalkyl, hydroxyl or halide
17 substituents whether or not further substituted in the ring
18 system by one or more other univalent substituents.

19 2. By substitution at the 3-position with an acyclic alkyl
20 substituent.

21 3. By substitution at the 2-amino nitrogen atom with alkyl,
22 dialkyl, benzyl or methoxybenzyl groups.

23 4. By inclusion of the 2-amino nitrogen atom in a cyclic
24 structure.

25 * * *

26 (vii) [Synthetic cannabinoids or any material, compound,
27 mixture or preparation which contains any quantity of the
28 following substances, including their analogues, congeners,
29 homologues, isomers, salts and salts of analogues, congeners,
30 homologues and isomers, as follows:

- 1 1. CP 47,497 and homologues, 2-[(1R,3S)-3-
- 2 hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol).
- 3 2. HU-210, [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
- 4 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] chromen-1-
- 5 ol)].
- 6 3. HU-211, (dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-6,6-
- 7 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
- 8 tetrahydrobenzo[c]chromen-1-ol).
- 9 4. JWH-018, 1-Pentyl-3-(1-naphthoyl)indole.
- 10 5. JWH-019, 1-Hexyl-3-(1-naphthoyl)indole.
- 11 6. JWH-073, 1-Butyl-3-(1-naphthoyl)indole.
- 12 7. JWH-200, (1-(2-morpholin-4-ylethyl)indol-3-yl)-
- 13 naphthalen-1-ylmethanone.
- 14 8. JWH-250, 1-pentyl-3-(2-methoxyphenylacetyl)indole.]

15 Synthetic cannabinoids including any material, compound, mixture
16 or preparation that is not listed as a controlled substance in
17 Schedule I through V, is not a Federal Food and Drug
18 Administration approved drug or used within legitimate and
19 approved medical research and which contains any quantity of the
20 following substances, their salts, isomers, whether optical
21 positional or geometric, analogues, homologues and salts of
22 isomers, analogues and homologues, unless specifically excepted,
23 whenever the existence of these salts, isomers, analogues,
24 homologues and salts of isomers, analogues and homologues if
25 possible within the specific chemical designation:

26 1. Tetrahydrocannabinols or tetrahydrocannabinols which is
27 naturally contained in a plant of the genus cannabis as well as
28 synthetic equivalents of the substances contained in the plant
29 or in the resinous extractives of Cannabis or synthetic
30 substances, derivatives and their isomers with similar chemical

structure and or pharmacological activity such as the following:

(A) Delta 1 cis or trans tetrahydrocannabinol and their optical isomers.

(B) Delta 6 cis or trans tetrahydrocannabinol and their optical isomers.

(C) Delta 3, 4 cis or their trans tetrahydrocannabinol and their optical isomers.

2. Naphthoxylindoles or any compound containing a 3-(-1-naphthoyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl) methyl or (terahdropyran-4-yl) methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall include the following:

(A) JWH 015.

(B) JWH 019.

(C) JWH 073.

(D) JWH 081.

(E) JWH 122.

(F) JWH 200.

(G) JWH 210.

(H) JWH 398.

(I) AM2201.

(J) WIN 55 212.

3. Naphylmethylinindoles or any compound containing a 1H-indol-3-yl-(1-naphthyl) methane structure with a substitution at the nitrogen atom of the indole ring by an alkyl,

haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl) methyl or (tetrahydropyran-4-yl) methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall include JWH 175 and JWH 184.

4. Naphthoylpyrroles or any compound containing a 3-(1-naphthoyl) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl) methyl or (tetrahydropyran-4-yl) methyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall include JWH 307.

5. Naphthylmethylindenes or any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl)methyl or (tetrahydropyran-4-yl) methyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall include JWH 176.

6. Phenylacetylindoles or any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,

alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-
pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl) methyl or
(tetrahydropyran-4-yl) methyl group, whether or not further
substituted in the indole ring to any extent and whether or not
substituted in the phenyl ring to any extent. This shall include
the following:

(A) RCS-8 or SR-18.

(B) JWH 250.

(C) JWH 203.

(D) JWH 251.

(E) JWH 302.

7. Cyclohexylphenols or any compound containing a 2-(3-
hydroxycyclohexyl) phenol structure with a substitution at the
5-position of the phenolic ring by alkyl, haloalkyl, cyanoalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-
pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl) methyl or
(tetrahydropyran-4-yl) methyl group, whether or not substituted
in the cyclohexyl ring to any extent. This shall include the
following:

(A) CP 47, 497 and its homologues and analogs.

(B) Cannabicyclohexanol.

(C) CP 55, 940.

8. Benzoylindoles or any compound containing a 3-(benzoyl)
indole structure with substitution at the nitrogen atom of the
indole ring by alkyl, haloalkyl, cyanoalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)
methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-pyrrolidinyl)
methyl, 1-(N-methyl-3-morpholinyl) methyl or (tetrahydropyran-

4-yl) methyl group, whether or not further substituted in the
indole ring to any extent and whether or not substituted in the
phenyl ring to any extent. This shall include the following:

(A) Am 694.

(B) Pravadoline WIN 48098.

(C) RCS 4.

(D) AM-679.

9. [2,3-Dihydro-5 methyl-3-(4-morpholinylmethyl) pyrrolo
[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-napthalenymethanone. This
shall include WIN 55, 212-2.

10. (6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3(2-
methyloctan-2-yl)-6a, 7, 10, 10a-tetrahydrobenzo [c]chromen-1-
old 7370. This shall include HU 210 and HU 211.

11. Adamantoylindoles or any compound containing a 3-(-
1adamtoyl) indole structure with substitution at the nitrogen
atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-
pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl) methyl or
(tetrahydropyran-4-yl) methyl group, whether or not further
substituted in the adamantyl ring system of any extent. This
shall include AM 1248.

12. Tetramethylcyclopropanoylindoles or any compound
containing a 3-tetramethylcyclopropylindole structure with
substitution at the nitrogen atom of the indole ring by analkyl,
haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethy, 1-(N-methyl-2-piperidinyl) methyl, 2-(4-
morpholinyl) ethyl, 1-(N-methyl-2-pyrrolidinyl) methyl, 1-(N-
methyl-3-morpholinyl) methyl or (tetrahydropyran-4-yl) methyl
group whether or not further substituted in the indole ring to

1 any extent and whether or not substituted in the
2 tetramethylcyclopropanoyl ring to any extent. This shall include
3 UR-144.

4 13. Any other synthetic chemical compound that is a
5 cannabinoid receptor agonist and mimics the pharmacological
6 effect of the naturally occurring cannabinoids that is not
7 listed in Schedules II through V, not an Federal Food and Drug
8 Administration approved drug or used within legitimate, approved
9 medical research.

10 * * *

11 Section 2. This act shall take effect in 60 days.